NCT06607445 Evaluation of the Implementation of the Pharmacogenetics and Personalized Medicine Program "MedeA" in the Extremadura Health Service.
| NCT ID | NCT06607445 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Complejo Hospitalario Universitario de Badajoz |
| Condition | Adverse Drug Event |
| Study Type | OBSERVATIONAL |
| Enrollment | 6,445 participants |
| Start Date | 2021-05-26 |
| Primary Completion | 2024-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 6,445 participants in total. It began in 2021-05-26 with a primary completion date of 2024-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
An open longitudinal observational study, non-randomized, which will include the adult population, attended by the SES, in which preference will be given to those patients under treatment with drugs that can produce relevant adverse effects. It is a naturalistic study in which no pharmacological or other type of intervention will be carried out, only the information recommended in the drug data sheet (pharmacogenetic biomarkers, relevant interactions and clinical contraindications) will be provided.
Eligibility Criteria
Inclusion Criteria: Patients with a recent diagnosis and who are to be or are being treated according to usual clinical practice, who meet the criteria to participate in the study, read the corresponding information sheet, sign informed consent and agree to participate, provided they meet the following inclusion criteria: General criteria for all patients: * Age ≥ 18 years. In case of minors, they may be included, under the following assumptions: * If the minor is under 12 years of age, participation will require the consent and signature of the informed consent document by both parents (or their guardian). * If the minor is between 12 and 16 years of age, a proxy informed consent form will be provided and signed by both parents (if both parents are present at the time of the interview) or only one of them (in which case one of the following two conditions must be stated: that the other parent is not present at the time of the interview but does not object to the participation of the minor in the study or that the signatory is the sole legal guardian of the minor). * Be registered or potentially/have been attended in the Extremadura Health Service. * Not have language or communication barrier or present disability being totally dependent on another person. Exclusion Criteria: * Failure to meet any of the inclusion criteria described above. * Refusal by the patient to be part of the cohort initially, or to continue to be part of the cohort during follow-up. * Manifest difficulty for follow-up.
Frequently Asked Questions
Who can join the NCT06607445 clinical trial?
This trial is open to participants of all sexes, studying Adverse Drug Event. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06607445 currently recruiting?
Yes, NCT06607445 is actively recruiting participants. Visit ClinicalTrials.gov or contact Complejo Hospitalario Universitario de Badajoz to inquire about joining.
Where is the NCT06607445 trial being conducted?
This trial is being conducted at Badajoz, Spain.
Who is sponsoring the NCT06607445 clinical trial?
NCT06607445 is sponsored by Complejo Hospitalario Universitario de Badajoz. The trial plans to enroll 6,445 participants.